+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Treatment of Precocious Puberty with a Long-Acting Preparation of D-Trp 6-LHRH

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          D-Trp<sup>6</sup>-LHRH was tested in 6 girls 1–8 years old and 7 boys 2–10 years old with precocious puberty. All children had advanced bone age, breast or testis enlargement and a pubertal LH response to LHRH. 60 µg LHRH-A/kg body weight was given intramuscularly on days 1 and 21 and thereafter every 4 weeks for 6–21 months. In girls, breast enlargement disappeared and mean uterus size decreased within 6 months. Mean ovary length decreased from 25.0 ± 1.9 to 16.0 ± 2.7 (p < 0.02). In boys, mean testis volume decreased from 8.0 ± 1.1 to 6.7 ± 1.4 ml (p < 0.05) within 6 months. In both sexes, growth velocity decreased significantly and bone maturation was reduced. Plasma levels of estradiol or testosterone and FSH levels decreased significantly within 3 weeks. The LH response to LHRH was reduced to normal prepubertal values after 7 weeks. No secondary clinical or biochemical escape occurred. No side effects occurred except for transient vaginal bleeding in one girl after the first and second injection. No antibodies to LHRH-A were detected in the patients’ sera. This study demonstrates the ability of a delayed release formulation of D-Trp<sup>6</sup>-LHRH to suppress pituitary and gonadal secretion and pituitary response to LHRH for as long as 2 years of therapy. This treatment appears to be more efficient in treating both clinical and biochemical abnormalities than does treatment with inhibitory steroids. Additionally the method of administration is more practical and ensures better patient compliance.

          Related collections

          Author and article information

          Hormone Research in Paediatrics
          S. Karger AG
          28 November 2008
          : 28
          : 2-4
          : 155-163
          Hôpital St.-Vincent-de-Paul, Paris; Fondation de Recherche en Hormonologie, Fresnes, France
          180939 Horm Res 1987;28:155–163
          © 1987 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 9
          Recent Advances in the Pharmacological Control of Gonadal Function


          Comment on this article